Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.54 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.54 |
| ▸ | PDE4A | P27815 | 1/20 | 0.54 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | APEX1 | P27695 | 1/20 | 0.48 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | NR1H4 | Q96RI1 | 4/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | PPM1B | O75688 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14769640 | 1.00 | ESR1 (0.54) | ESR1PTGS1PDE4AABCC2ALDH1A1 | |
| SCHEMBL18155184 | 1.00 | ESR1 (0.54) | ESR1PTGS1PDE4AABCC2ALDH1A1 | |
| SCHEMBL18710627 | 0.91 | ESR1 (0.52) | ESR1PTGS1PDE4AABCC2ALDH1A1 | |
| SCHEMBL14769622 | 0.85 | NPSR1 (0.51) | MEN1KMT2AEPHX2NPC1POLB | |
| SCHEMBL18155181 | 0.85 | NPSR1 (0.51) | MEN1KMT2AEPHX2NPC1POLB | |
| SCHEMBL18710626 | 0.84 | ESR1 (0.54) | ESR1PTGS1PDE4AABCC2ALDH1A1 | |
| SCHEMBL22251574 | 0.84 | ESR1 (0.54) | ESR1PTGS1PDE4AABCC2ALDH1A1 | |
| SCHEMBL18155287 | 0.84 | ESR1 (0.54) | ESR1PTGS1PDE4AABCC2ALDH1A1 | |
| SCHEMBL21092645 | 0.84 | ESR1 (0.54) | ESR1PTGS1PDE4AABCC2ALDH1A1 | |
| SCHEMBL6929089 | 0.81 | GAA (0.52) | ESR1PTGS1PDE4AABCC2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11564908-B2 | Beta-lactam compounds or salts thereof for use in long-acting prevention or treatment of a glucose metabolism disorder | GLYCOLYSIS BIOMED CO., LTD. (TW) | 2023-01-31 | — | — | US | disclosed |
| US-20200230149-A1 | BETA-LACTAM COMPOUNDS OR SALTS THEREOF FOR USE IN LONG-ACTING PREVENTION OR TREATMENT OF A GLUCOSE METABOLISM DISORDER | GLYCOLYSIS BIOMED CO., LTD. (TW) | 2020-07-23 | — | — | US | disclosed |
| US-20200230105-A1 | BETA-LACTAM COMPOUNDS OR SALTS THEREOF FOR USE IN LONG-ACTING PREVENTION OR TREATMENT OF A GLUCOSE METABOLISM DISORDER | GLYCOLYSIS BIOMED CO., LTD. (TW) | 2020-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200230105-A1 | BETA-LACTAM COMPOUNDS OR SALTS THEREOF FOR USE IN LONG-ACTING PREVENTION OR TREATMENT OF A GLUCOSE METABOLISM DISORDER | SLC5A1, SLC5A2, MGAM | ESR1 4417/4885PTGS1 2617/4885PDE4A 1331/4885 |
| US-11564908-B2 | Beta-lactam compounds or salts thereof for use in long-acting prevention or treatment of a glucose metabolism disorder | SLC5A1, SLC5A2, MGAM | ESR1 4417/4885PTGS1 2617/4885PDE4A 1331/4885 |
| US-20200230149-A1 | BETA-LACTAM COMPOUNDS OR SALTS THEREOF FOR USE IN LONG-ACTING PREVENTION OR TREATMENT OF A GLUCOSE METABOLISM DISORDER | SLC5A1, SLC5A2, MGAM | ESR1 4417/4885PTGS1 2617/4885PDE4A 1331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.